PSTX News and Press, Poseida Therapeutics Inc. From 05/22/23

Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis PR Newswire SAN DIEGO , May 22, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advanci...

2023-05-19 17:30:11 ET Gainers: WISeKey International Holding ( WKEY ) +6% . Viracta Therapeutics ( VIRX ) +5% . Fossil Group ( FOSL ) +5% . OmniAb ( OABI ) +5% . Lifecore Biomedical ( LFCR ) +4% . Losers: Jupiter Wellnes...

Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting PR Newswire Six presentations highlight significant advancements across the Company's Gene Therapy platform ...

2023-05-09 17:55:30 ET Poseida Therapeutics press release ( NASDAQ: PSTX ): Q1 GAAP EPS of -$0.45 misses by $0.03 . Revenue of $10.34M (+618.1% Y/Y). For further details see: Poseida Therapeutics GAAP EPS of -$0.45 misses by $0.03, revenue of $10.34M

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023 PR Newswire Highlighted significant research, preclinical advances and platform technology progress at third annual R&D Day Appointed Kristin Yarema , Ph.D., as President,...

Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting PR Newswire SAN DIEGO , May 2, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy compan...

Poseida Therapeutics to Present at BofA Securities 2023 Health Care Conference PR Newswire SAN DIEGO , May 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for pa...

2023-04-25 08:35:07 ET Summary Updated results from phase 1 studies, using P-MUC1C-ALLO1 for epithelial cancers and P-BCMA-ALLO1 for multiple myeloma, are expected at upcoming medical conference in 2023. Partnership with Roche to advance several allogeneic CAR-T cell therapies; Po...

2023-04-24 14:19:46 ET Summary Poseida Therapeutics is developing cell and gene therapies for cancer and rare diseases, with a focus on solid tumor cell therapy. The company's lead product candidate, P-MUC1C-ALLO1, is in a Phase 1 trial for treating various solid tumors, including...

Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors PR Newswire SAN DIEGO , April 13, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for pat...